Cytokines News and Research

Latest Cytokines News and Research

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

AI used to define the cytokine storm implicated in fatal COVID-19

A new study published on the preprint server bioRxiv* in September 2020 reports the use of artificial intelligence (AI) to identify an invariant or universal host immune response found in all viral pandemics so far. The association of this response with severe COVID-19 phenotypes indicates a new understanding of the human immune response in viral pandemics.

24 Sep 2020

Polyphenolic compound offers new therapeutic option for chronic inflammatory disorders

Various plants and their products are known to contain "bioactive" ingredients that can alleviate human diseases. These "phytocompounds" often contain restorative biological properties such as anti-cancerous, antioxidant, and anti-inflammatory effects.

24 Sep 2020

Children exhibit distinct immune system responses against COVID-19

Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept. 18 in the journal Science Translational Medicine.

23 Sep 2020

Exercise hormone could have a therapeutic effect on COVID-19 patients

A study conducted by researchers at São Paulo State University suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients.

22 Sep 2020

Study detects key differences in immune responses of adults and children with COVID-19

The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults.

22 Sep 2020

Study: Greater exercise capacity is linked to decreased mortality risk in people with type 2 diabetes

New research presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year, shows that having a greater exercise capacity is associated with a significantly decreased all-cause mortality risk of between 25-33% in people with type 2 diabetes (T2D).

21 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

Novel sequencing method could be useful for COVID-19 research

Researchers at the University of Chicago and the Cleveland Clinic have presented a novel single-cell RNA sequencing method that could be a useful application for research into the current coronavirus disease 2019 (COVID-19) pandemic.

20 Sep 2020

Scientists identify new drug to prevent SARS-CoV-2 infection consequences

Scientists from the Department of Cell Biology of the University of Malaga and the Andalusian Centre for Nanomedicine and Biotechnology have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

19 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

T cells on the front line of COVID-19 response

In the new study, published in the journal Cell, the team has found that the uncoordinated responses produced by the immune system, especially in people who are more than 65 years old, maybe the reason why older adults are more at risk.

17 Sep 2020

Biomarker predicts disease severity in COVID-19 patients

Airway cell analyses showing an activated immune axis could pinpoint the COVID-19 patients who will most benefit from targeted therapies.

17 Sep 2020

CNIC researchers uncover a mechanism explaining how macrophages regulate obesity

Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.

17 Sep 2020

LOX-1-immature neutrophils may help identify COVID-19 patients at risk of thrombosis complication

To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Biologic therapy for psoriasis could lead to significant reduction in heart disease

Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research published today in Circulation: Cardiovascular Imaging, an American Heart Association journal.

15 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Central nervous system immune responses to COVID-19

A recent study published on the preprint server bioRxiv by scientists from Yale School of Medicine, University of California, Yale School of Public Health, Yale University, and Howard Hughes Medical Institute examined the impact of SARS-CoV-2 infection on the central nervous system.

14 Sep 2020